Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares

Grade Last Price % Change Price Change
grade B 3.2942 1.34% 0.04
KZIA closed up 1.34 percent on Monday, October 14, 2019, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical KZIA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 1.34%
Narrow Range Bar Range Contraction 1.34%
NR7 Range Contraction 1.34%
NR7-2 Range Contraction 1.34%
Wide Bands Range Expansion 1.34%
Gapped Down Weakness 1.34%

Older signals for KZIA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
KZIA Chart by TradingView
Basic chart:
Profile
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Biotechnology Cancer Organ Systems ATM Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
Is KZIA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 13 Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
Sep 12 St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
Jul 22 Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
Jul 17 Kazia calls for greater awareness of the deadliest brain cancer in the US
Jun 4 How Kazia Therapeutics Limited (ASX:KZA) Can Impact Your Portfolio Volatility
May 20 Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
May 9 New positive data from phase IIa trial in brain cancer patients
May 8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US
May 8 Kazia calls for greater awareness of the most lethal women's disease in Australia
Apr 19 Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
See more KZIA news...
Indicators
Indicator Value
52 Week High 4.27
52 Week Low 2.04
Average Volume 3,385
200-Day Moving Average 2.9892
50-Day Moving Average 2.8786
20-Day Moving Average 3.4379
10-Day Moving Average 3.464
Average True Range 0.2615
ADX 18.03
+DI 19.8465
-DI 25.6215
Chandelier Exit (Long, 3 ATRs ) 3.1655
Chandelier Exit (Short, 3 ATRs ) 3.4345
Upper Bollinger Band 3.8838
Lower Bollinger Band 2.992
Percent B (%b) 0.34
BandWidth 25.940254
MACD Line 0.1426
MACD Signal Line 0.2065
MACD Histogram -0.0639
Fundamentals Value
Market Cap 15.91 Million
Num Shares 4.83 Million
EPS -1.80
Price-to-Earnings (P/E) Ratio -1.83
Price-to-Sales 2.05
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.29
Resistance 3 (R3) 3.29 3.29 3.29
Resistance 2 (R2) 3.29 3.29 3.29 3.29
Resistance 1 (R1) 3.29 3.29 3.29 3.29 3.29
Pivot Point 3.29 3.29 3.29 3.29 3.29
Support 1 (S1) 3.29 3.29 3.29 3.29 3.29
Support 2 (S2) 3.29 3.29 3.29 3.29
Support 3 (S3) 3.29 3.29 3.29
Support 4 (S4) 3.29